Sheet 1 of 2

FORM PT0-1449	U.S. DEPARTMENT OF COMMERCE		ATTY. DOCKET NO.	APPLICATION SERIAL NO.
(REV 8-83)	PATENT AND TRADEMARK OFFICE		P-0800(0)-2	08/462,148
INFORMATION	N DISCLOSURE CITATION	RV	MILAPPICANT	
	several sheets if necessary)	(27°	Hyal Pharmaceutical	Corporation
		17. S.	JELING DATE 1996 June 5, 1995	GROUP 1211
		9000	Office and the second s	

U.S. PATENT DOCUMENTS

XAMINER NITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CP	4,141,973	02-1979	Balazs			
4	4,582,865	04-1986	Balazs et al.			
y	4,636,524	01-1987	Balazs et al.			
(n	4,711,780	12-1987	Fahim			
(0	4,725,585	02-1988	Wenge et al.			
in	4,736,024	04-1988	Della Valle et al.			
6	4,755,544	07-1988	Makino et al.			
Sp	4,795,741	01-1989	Leshchiner et al.	_	<u> </u>	
6	4,801,619	01-1989	Lindblad	_		
<i>V</i> 2	4,808,576	02-1989	Schultz et al.			
5	4,814,176	03-1989	Makino et al.			
(r	4,840,941	06-1989	Ueno et al.		<u> </u>	
in	4,851,521	07-1989	della Valle et al.		<u> </u>	<u> </u>
(g	4,937,254	06-1990	Sheffield et al.	_	<u> </u>	
' 2	4,957,744	09-1990	della Valle et al.	_	<u> </u>	
<u> </u>	4,965,353	10-1990	della Valle et al.		<u> </u>	
40	4,970,298	11-1990	Silver et al.		 _	
- 1	07/338,106	04-1989	Falk	1=		
- 	17000,200	1-1-1-1				

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS YES	NO
ap	1,205,031	05-1986	Canada				
اور	1,240,929	08-1988	Canada				
Co	0 138 572	04-1985	Europe				
Lo	0 179 442	04-1986	Europe				
y	0 197 718	10-1986	Europe				
5	0 208 623	01-1987	Europe		 		
y	0 216 453	04-1987	Europe				-
Cr	0 224 987	06-1987	Europe		<u> </u>		ــــــــــــــــــــــــــــــــــــــ

FORM PT	0-144	9 U.S. DEPART	COMMERCE	ATTS	DOCKETNO	·			
(REV. 8-8		PATENT AND TRADE			00(0)-2	_	APPLICATIONS 08/462,	FRIAL NO	
INFORM	/AI	TION DISCLOSURE C	TATION		ICANT	<u>.</u>			
		(Use several sheets if necessar	y) 		l Pharmace	utical	Corporati	lon	
	_			AFILE	GDATE	T	GROUP		
					1995	<u></u>	12	11	
	•		FORE	GN PATE	NT DOCUM	MENTS			
		DOCUMENT NUMBER	DATE	COURT ON THE	TTD. V.	Q.A.	SS SUBCLASS	IRANS YES	LATION
(n		0 240 098	10-1987	Europe	•	-			.10
in		0 265 116	04-1988	Europe					
SI		0 270 317	06-1988	Europe		-			
m		0 285 357	10-1988	Europe					
ly		0 287 210	10-1988	Europe		_			
_ ~		0 295 092	12-1988	Europe					
L'on		0 296 740	12-1988	Europe					
				•					
	-	63/045223		Japan-	English	transla	ion will	follow	<u> </u>
SP		61000017	01-1986		English				
74								T	i -
		WO 88/07060	09-1988	PCT					
		WO 89/07932	09-1989	PCT					
	1	WO 91/04058	04-1991	Int'l Se	arch Rep	ort			
		·							
		OTHER DO	CUMENTS	(Including	Author, Title,	Date, Po	ertinent Page	es, Etc.)	•
Cp		Sandra Blakes 1989 edition	of the Glob	be and M	ail, Toron	to, On	tario, Pag	e D4.	
G,		Pam Harrison,	"Toxic di	rug tameo	but still	potent	" Ontario	Med	licine,
9/		Volume 8, No	o. 16 dated	August	21, 1989,	Page	1.		
4		The Merck Ir	dex Eleve	nth Edition	on, Center	nnial E	dition, H	yaluro	onic Acid
		formulation,	Pages 751	and 752	•				
ري		Alan R. Liss,	Inc., Mod	ulation o	f Immunit	ty in C	ancer Par	tients	by
<i>y</i> ,	-	Prostaglandin	Antagonis	ts, <u>Imm</u>	unity to C	Cancer	II (will	follow	')
,		Goodwin, J.S.	_						
5	,	Immunotherap	•		_			_	
		Agents in Ca	ncer Thera	<u>py</u> , Rave	n Press, N	lew Yo	ork, (1981	<u>) (w</u>	ill follow)
		Dr. Samuel A							
\v		Surfactants",	Antimicrob	oial Age	nts and	Chemo	therapy,	April	1978, pp.
		686-690. (wil	l follow)						
EXAMI	NEF	2/ 0 0			DATE C	ONSIDE	_		
		h Pelh			<u> </u>		1-96		
EXAMINE		Initial if citation co	nsidered, wheth	er or not ci	tation is in co	onformance	with MPEP	609; D	raw line through
[citation if	f no	t in conformance and n	ot considered.	Include copy	of this form	with nex	II communicat	1071 IO 1	ippiicant.

PORM	PTO-1	449 (1 ENTS	AND	ed) ~ ≈	: KCA	TO STREET	<u> </u>	ATTY. DOCKET P-0800(0)-	HO. 2	S	08/46		3
APPL		S	ATE	eit		ીંહેઇ		Hyal Pharma		cal	Corpo	ratio	on.
	(Une s	SAR.3		63 H :		- Vi		S FLUIS CATE June 5, 199)5	G	adur	1211	
1875°	24CE (XXX	244.7 0	CH_		U.S. PA		BOOL PEUR					
ERRER HTML		נפ	aket	√.SE	3	DATE -		WE	c	kS\$	23CKE	FATT	-
	AA				I								
	16	4	 	11		 					ļ.		
	10		- -	1-1	_‡_	<u> </u>	<u> </u>						
	10	 	 	++		-	-				 		
	NF.		+	++	+	 	├				 	 	
	AG AG		++	++		 	 				 	 	
	W .	1	++-	++	-+-	 	1						
	A												
	N		\prod		T						 	!	
	I K			11			<u> </u>		1_		┸	<u> </u>	
					FC	REIGN	PAT	ENT DOCUMENT	rs				
					_		1	~~ L==	١,	225	SECISS	746	אבונית
	<u> </u>	X		1,24	31 	DATE		二二		<i></i>	35.00	18	NO
	1	12/6	131	1:-	<u> </u>	12:0,90	1-	0.31.2. 3.2. 3		<u></u>			<u> </u>
	H	13/5			-10	1-2718	1 =	re			<u> </u>		
	H	1-	i.L	<u> </u>	<u> </u>	3 5	1		==				
	10			- -	-		1						
	+	++	╬┼	+	+		+		_		 	†	Í
	1 10	4					1	- THE Date Co	<u> </u>	2	- El	<u> </u>	.'
	חט	ER		LAT	([:::::::::::::::::::::::::::::::::::::	tucing /	LUCK	x, Title, Date, Pe			ogat =1	<u></u>	
	JAR.	-											
	AS.												
					, ,								
	A	-											
<u> </u>	FEREN							DATE CONSC)ERED				
													اخد ہے۔
ಒಂದಾ	and t	3	Ene t	~~		ಜಪಾಲಗ ಗ		wherer or not a conformance a	של אסני הבי אסני	n ≥ ⇔n	ಟ್ಟ್ ಯಗರು ಶರರ್ಚಿತರೆ.	indud Indud	ie sos
र्ज क्षेत्रं	mci :	With	CAX.	المحت		-25000	T 8	Special II.					
៊ុកវ	ormati	on Di	scies	sure	Stat	ement—	Sect	ion 9 PTC-1449 ((Modifi	ed)	[6-1]—7	age —	<u></u> -⊃f \

*This was taken from Application Serial NO. 07/675,908

UST	OF PA	E	Еп	AH	10	PUE	3UC	ATIC	NS.P	OR	F	-080	00(0))-2		•	08/46		3
APPL	JCANT	73	H	CR	М		N D	sa.	OSU	*		PUC							
	(Uee	ر نوو							E7	DEC	· @	ya1	Phai	mac	euti	ca	1 Cor	porat	ion
	,,,,,,								2 5]] <u>2</u> 1996	J_1	ujje ujje	DATE 5, 1	995		G	ROUP	1211	L
REFER	ENCE	Œ	SG	W.	00	H		ŭ		ATENT Rosensola	300	CHEN	TS.						_
EXHIBITING NETHER			000	JÆ.	9(7 X	C) (E	8		DATE	W. W.		XAME			ထေ	3	2,800,63	1	DATE CARATE
	M																		
	AB			_	_		_			<u> </u>									
	10	Н					+	+-											
	Æ			\dashv			十	+		+		-						 	-
	H																		
	AG						1	Ļ		1									
	M	-				Н	-	╫		-								-	
	N	十			-		1	+		 								+	
	Ж							工											
	_						F	CRE	!!GN	PATE	NT I	2000	JME	ITS					
			***						847			···	,					TRAKE	MOTAE
			ш.		A(.	œ			DATE		(הואננג	1		as	N)	SBCUS	YE	жо
	AL.						\top	T		1								1	
	All						T	\top		1						-		T	
	,AN							\top										7 -	
	Ю						Ť	十		1									1
	NP.						十	\top		1									1
	OTI	IE			A	77	(inc	duc	ing /	Author	r, Tit	ie, D	ate, F	erti	nent	Pa	çes, El	c)	
																_			
	AR	-	-																
	!	┢	-									-	·						
	AS.																		
			L								·								
	-																		
	NT	Γ																	
ĐAN	PER	1	1		-						С	ATE (CNS.	CERE	Ð				
									<u> </u>				ـــــــــــــــــــــــــــــــــــــ	۔۔نہ		- i	confr	man:	a with
EXAMII MPEP (of this	309 . C	XZ	WE	ne	th	TOU	gh (HE	ion if	not in	CONT	OUL		0.020 2.021 ∩	iot co	XTS	dered.	includ	ထင္
				_									1440	(11-	4187	n re	. 17	ace –	
(Infor	matic	ט נ	Disc	c!c	sui	re S	Stat	eme	ent	Sectio	n 9 i	- 10-	1449	(MO	ıııea) re	i-1]—p	عود)

This was taken from Application Serial No. 07/675,908

Sh	e	et	1	of	1

FORM PTO-1449 U.S. DEPARTMENT PATENT AND TRADE		ATTY. DOCKET NO.	SERIAL NO. 08/462,148
Information Disclosure Statement by Applicant		APPLICANT Hyal Pharmace	utical Corporation
(Use several sheets if necessary)	19.	FING DATE	GROUP 1211

U.S. PATENT DOCUMENTS

Exme		Document Number	Date	Name	Class	Sub Class	Filing Date
W		5,166,331	11/24/92	della Valle et al.			
· bi		5,095,037	03/10/92	Iwamitsu et al.			
	<u> </u>		L		<u> </u>		
	ļ	L	<u> </u>		<u> </u>		
<u> </u>	<u> </u>				ļ		
ļ		<u> </u>		<u> </u>			
-			-		 	 	
<i>'</i>		 			<u> </u>		
——					 	 	
 							
					1		

FOREIGN PATENT DOCUMENTS

Exmr Initial	Document Number	Date	Country	Class	Sub Class	Translation YES NO
(m)	AUB14534/8	8 11/10/90	Australia			
in	WO88/07060	09/22/88	PCT	·	1	
42	AUB17459/8	8 12/15/88	Australia			
14	WO89/05645	06/29/89	PCT			
in	62-201825	09/05/87	Japan (English Translation)			
V	62-287041	11/17/89	Japan (English Translation)			
					<u> </u>	<u> </u>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	(Including Author, Ti	tle, Date, Pertinent Pages, Etc.)
Examiner	a Pedler	Date Considered 6-6-96

Sheet 1 of 6

FORM PT0-1449 (REV. 8-83)	PATENT AND TRADEMARK OFFICE	12 P-0800(0)-2	08/462,148
1	OUNT OF THE PROPERTY OF THE PR	990 APPLIFANTS Pharmaceutica	
		FILING DATE	GROUP
		June 5, 1995	1211

U.S. PATENT DOCUMENTS

EXAMINER INTTIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Ln	2,583,096	01 1952	Hadidian et al			
6	3,436,454	04-1969	Nouvel			
4	3,887,703	06-1975	Manoussos et al			
4	4,272,522	06-1981	Balazs			
un	4,716,224	12-1987	Sakurai et al.	_		
И	4,853,226	08-1989	Machida et al.		<u> </u>	
10	4,946,870	08-1990	Partain, III. et al.			
FOREIC	N PATENT DOCUMENT	rs			Sub	,
	Document No.	Date	Country	Class	Class	YES NO
G	B-72117/87	12-1987	Australia			
6	B-17459/88	12-1988	Australia			
y	30806/84	07-1984	Australia			
				<u> </u>		
Co	0,378,852	12-1989	Europe			
-						
(0)	1,283,892	08-1972	Great Britain		—	
4	2,099,826-A	12-1982	Great Britain			
<u> </u>						
	A-116678/88	11-1989	Japan			Yes
So	Application	Laid-Open-to-Publi	1 -			<u> </u>
60	61-233,622	10-1986	Japan		<u> </u>	No_
w	57-183,707	12-1982	Japan		1	Yes
Lp	2,364,373	10-1975	Germany		 _	Yes

^{*}This was taken from Application Serial No. 07/675,908

FORM PT0-1449 U.S. DEPARTMENT OF COMMERCE (REV. 8-83) PATENT AND TRADEMARK OFFICE	18	ATTY DOCKET NO.	APPL 08/462,	ICATION SERIAL NO.
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	V PAT &	Depuicants 12 Hya16 Pharmaceutical	Corporat	ion
·		June 5, 1995	GROUP	1211

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

G	Alaverdyan MI, Ter-Avetisyan AT. Effect of hyaluronidase, hyaluronic acid, and some other substances on postradiational experimental bacteriemai. Bulletin of Experimental Biology and Medicine 1967; 64(9): 967-969.
\lambda_n	Balazs EA, Gibbs DA. The rheological properties and biological function of hyaluronic acid. In: Chemistry and Molecular Biology of the Intercellullar Matrix. Volumes III. New York: Academic Press, 1970. PP. 1241-1253.
G	Balazs EA, Band P. Hyaluronic acid: Its structure and use. Cosmetics & Toiletries . Polymers in Cosmetics 1984; 99: 65-72.
Sp	Camber O, Lundgren P. Diffusion of some low molecular weight compounds in sodium hyaluronate. Acta Pharmaceutica Suecica 1985; 22(6): 315-320.
(p	Camber O, Edman P, Gurny R. Influence of sodium hyaluronate on the meiotic effect of pilocarpine in rabbits. Current Eye Research 1987; 6(6): 779-784.
Sp	Chang S-C. Pro-drug and vehicle approaches to improve the therapeutic index of topically applied timolol in the pigmented rabbit. Dissertation Abstracts International 1988; 49(2): 367-B.

FORM PT0-1449 U.S. DEPARTMENT OF COMMERCE (REV. 8-83) PATENT AND TRADEMARK OF FILE C	ATTY. DOCKET NO. P-0800(0)-2	APPLICATION SERIAL NO. 08/462,148
INFORMATION DISCLOSURE CITATION 996 (Use several sheets if necessary)	APPLICANTS Hyal Pharmaceutica	l Corporation
,	FILING DATE June 5, 1995	GROUP 1211

	Cravioto, R.O., et al. Effects of Precipitates Formed by Insulin with Hyaluronic Acid and Mucoid From Vitreous Humor in Depressing Blood-Sugar
lp	Levels Science (1950); Vol. 111: 520-521
y	Gieldanowski, Jerzy; Skowronska, Jadwiga Studies on immunosuppressive and anti-inflammatory effect of adriamycin. Arch. Immunol. Ther. Exp. (1980); 28 (3): 439-446
6	Hassan HG, Akerman B, Ranck H, Lindberg B, Lindquist B. Effects of adjuvants to local anaesthetics on their duration. Acta Anaesthesiol. Scand. 1985; 29: 384-388.
6	Hurd ER Immunosuppressive and anti-inflammatory properties of cyclophosphamide, azathioprine and methotrexate. Arthritis and Rheumatism (1973 Jan-Feb); 16 (1): 84-88
6	Idson B. Polymers in skin cosmetics. Cosmetics & Toiletries 1988; 103: 63-68.
(m	Johansson A, Hassan H, Renck H. Effects of adjuvants to local anaesthetics on their duration. Acta Anaesthesiol. Scand. 1985; 29: 736-738.
G	Kalbhen D.A. The inhibitory effects of steroidal and non-steroidal antirheumatic drugs on articular cartilage in osteoarthrosis and its counteraction by a biological GAG-peptide complex (Rumalon®). Z. Rheumatol (1982): 41: 202-211

FORM PT0-1449	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	APPLICATION SERIAL NO.
(REV. 8-83)	PATENT AND TRADEMARK OFFICE	P-0800(0)-2	08/462,148
	N DISCLOSURE CITATION	APPLICANTS	
(Use several	sheets if necessary)	Hyal Pharmaceut	ical Corporation
٠.		FILING DATE June 5, 1995	GROUP
		PA	1211

Ч	Katsu M., Abe T., Shimada S. Significance and clinical use of non-steroid anti-inflammatory drugs as substitutes for steroids in steroid dependence. Nippon Rinsho (1968 Jan); 26(1): 89-95
h	Kreis H, Chkoff N, Droz D, et al. Nonsteroid anti-inflammatory agents as a substitute treatment for steroids in ATGAM-treated cadaver kidney recipients. Transplantation (1984 Feb.); 37(2): 139-145
lo	McIlwraith W. Current concepts in equine degenerative joint disease. Journal of the American Veterinary Medical Association 1982; February 1: 239-250.
G	Mizushima, Y. Possibility of non-steroid anti-inflammatory drugs as a substitute for steroids-analysis of the present situation and demands for the future. Nippon Rinsho (Jan. 1986); 26(1): 61-65
ζη	Nizolek DJH, White KK. Corticosteroid and hyaluronic acid treatments in equine degenerative joint disease: A review. The Cornell Veterinarian 1981; 71(4): 355-375.
Cp	Pigman W, et al. Acide hyaluronique et facteurs de perméabilité tissulaire. Bull. Soc. Chim. Biol. 1963: 5(2-3): 185-202.
6	Pruett RC, Schepens CL, Constable IJ, Swann DA. Hyaluronic acid vitreous substitute. In: Vetreous Surgery and Advances in Fundus Diagnosis and Treatment. Freeman H.M., et al., Editors. Appleton-Century-Crofts, 1977: Chapter 55 pp. 433-444.

FORM PT0-1449 U.S. DEPARTMENT OF COMMERCE (REV. 8-83) PATENT AND TRADEMARK OFFICE	ATTY. DOCKE P-0800(0)	ia reichtio	N SERIAL NO.
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	APPLICANTS HyaD Phari	maceutical Corporation	
	FILING DATE 1990 June 5,	1995 GROUP 1211	

•		
	lop	Reim M, Teping C. Surgical procedures in the treatment of most severe eye burns. Acta Ophthalmologica 1989-Supplementum 192; 67: 47-54.
	4	Rydell NW, Balazs EA. Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of osteoarthritis and on granulation tissue formation. Clinical Orthopaedics and Related Research 1971; 80(October): 25-29.
	G	Saba P, Galeone F, Salvadorini F, Guarguaglini M, Ombrato M. Investigation of the antihyperlipemic activity of an association of clofibrate and extractive mucopolysaccharide complex. Current Therapeutic Research 1978; 23(4): 455-463.
	Cy,	Stegman R, Miller D. Use of sodium hyaluronate in severe penetrating ocular trauma. Acta Ophthalmol. 1986; 18: 9-13.
	4	Trabucchi E, Foschi D, Marazzi M, Radaelli E, Lucianetti A, Rizzitelli E. Baratti C, et al. Prevention of wound dehiscence in severely obese patients with jejuno-ileal by-pass: The role of hyaluronic acid. Pharmatherapeutica 1988; 5(4): 233-239.
	G	Sertoli P, Merello A, Parodi M. L'acido jaluronico, per uso topico, nella cura delle ulcere trofocircolatorie degli arti inferiori. (Comunicazioni). Giornale Italiano di Dermatologia 1970; 45(8): 468-471.
	so	Walther, M. The Prevention of Strine Cutis Distansae During Pregnancy. Mineva Gynecolgia (1981) Vol. 33: 497-499

FORM PT0-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	APPLICATION SERIAL NO.
`		P-0800(0)-2	08/462,148
	chapte if managed \(\begin{array}{c} \empty	APPLICANTS THYAI Pharmaceutic	cal Corporation
	Trave	996 FILING DATE	GROUP 1211

W

Weirich, E.G., Longauer, J.K., Kirkwood, A.H.

Dermatopharmacology of salicylic acid. III. Topical contrainflammatory effect of salicylic acid and other durgs in animal experiments.

Dermatologica (1976); 152(2): 87-99

EXAMINER

a Rech

DATE CONSIDERED

6-696

Sheet 1 of 1

		10				
FORM PTO-1449	S. DEPARTMENT OF COMMERCE	21	11-1	DOCKET NO.	APPLICATION SERIAL NO.	
	ATENT AND TRADEMARK OFFICE			-6600(0)-2	08/462,148	
INFORMATION D	ISCLOSURE CITATION		1006AP	PLIĞÜNT		
(Use seve	ral sheets if necessary)	VPAN.	H	Pharmace	utical Corporation	
			FIL	ING DATE	GROUP	
			Jui	ne 5, 1995	1211	

U.S. PATENT DOCUMENTS

TAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,166,331	11-1992	Fidia			
	,	FOREIGN	PATENT DOCUME			
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
50	14534/88	11-1990	Australia			
50	15456/88	09-1988	Australia			
ري	17459/88	08-1991	Australia		<u> </u>	
G	29145/89	06-1989	Australia			
	62201825			sh trans		
	62287041		Japan - Engli	sh trans	lation	·
		<u> </u>				
	OTHER DOC	UMENTS (Inc	cluding Author, Title, D	Date, Pertin	ent Pages,	Etc.)
	OTHER DOC					

*This was taken from Applicatin Serial No. 07/838,674

Sheet <u>1</u> of <u>6</u>

FORM PTO-1449

(Rev. 2-32)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIATAY DOCKET NO.

SERIAL NO. 08/462,148

Information Disclosure Statement by Applicant

(Use several sheets if necessary)

That Pharmaceutical Corporation

GROUP

GROUP

June 5, 1995

1211

U.S. PATENT DOCUMENTS

Exmr Initial	Document Number	Date	Name	Class	Sub Class	Filing Date
b	4,141,973	2/79	Balazs			
4	4,582,865	4/86	Balazs et al.	•		
Le	4,636,524	1/87	Balazs et al.	,		
100	4,711,780	12/87	Fahim			
y	4,725,585	2/88	Wenge et al.			
w	4,736,024	4/88	Della Valle et al.			
io	4,755,544	7/88	Makino et al.			
Vr.	4,795,741	1/89	Leschiner et al.			
in	4,801,619	1/89	Lindblad			
is	4,808,576	2/89	Schultz et al.		-	
S	4,814,176	3/89	Makino et al.		<u> </u>	
Un	4,840,941	6/89	Ueno et al.			
4	4,851,521	7/89	della Vaile et al.			
√r	4,937,254	6/90	Sheffield et al.		F	
· 1/1	4,957,744	9/90	della Valle et al.			

FOREIGN PATENT DOCUMENTS

Exmr Initial	Document Number	Date	Country	Class	Sub Class	Translation YES NO
b	0 138 572	4/85	Еигоре			
40	0 179 442	4/86	Europe			
in	0 197 718	10/86	Europe			
50	0 208 623	1/87	Europe		_	
40	0 216 453	4/87	Europe		<u> </u>	
50	0 224 987	6/87	Europe			
40	0 240 098	10/87	Europe		—	
Gr 1	0 265 116	1/88	Europe			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Blakeslee, S., "Solid cores of tumors keeping out best drugs", July 8, 1989	P
edition of The Glove and Mail, Toronto, Ont., p. D4	
Harrison, P., "Toxic drug tamed but still potent", Ontario Medicine,	X [.]
Vol. 8, No. 16, 8/21/89, p. 1	
The Merck Index. Eleventh Edition, Centennial Edition,	<i>;</i> ;
Hyaluronic Acid formulation, pp. 751-752	
Braun, DP et al., "Modulation of Immunity in Cancer Patients by Prostaglandin	4 + 7
Antagonists", Immunity to Cancer II, 1989, pp 439-448, Alan R. Liss, Inc.,	
	edition of The Glove and Mail, Toronto, Ont., p. D4 Harrison, P., "Toxic drug tamed but still potent", Ontario Medicine, Vol. 8, No. 16, 8/21/89, p. 1 The Merck Index, Eleventh Edition, Centennial Edition,

Examiner & Redle	Date Considered	6696

Sheet 2 of

FORM PTO-1449 (Rev. 2-32)

U.S. DEPARTMENT OF COMME

Y. DOCKET NO. PATENT AND TRADEMARK 20(0)-2

SERIAL NO. 08/462,148

Information Disclosure Statement by Applicant

Pharmaceutical Corporation

(Use several sheets if necessary)

G DATE June 5, 1995

GROUP 1211

U.S. PATENT DOCUMENTS

Exmr Initial	Document Number	Date	Name	Class	Sub Class	Filing Date
Lo	4,965,353	10/90	della Valle et al.		Ciass	Date
G	4,970,298	11/90	Silver et al.			
4	4,684,627	8/87	LeVeen et al.		<u> </u>	+
ι_p	4,303 676	12/81	Balazs			+
4	5,166,331	11/92	della Valle et al.			
lp	5,095,037	3/92	Iwamitsu et al.			
W	2,583,096	1/52	Hididian et al.			
4	3,436,454	4/69	Nouvel			
S	3,887,703	6/75	Manoussos et al.		二 一	<u> </u>
W	4,272,522	6/81	Balazs			†
4	4,716,224	. 12/87	Sakurai et al.			†
V	4,853,226	8/89	Machida et al.		_	
B	4,946,870	8/90	Partain, III, et al.		—	1
		I		4		†

FOREIGN PATENT DOCUMENTS

Exmr Initial	Document Number	Date	Country	Class	Sub Class	Translation YES 1 NO
4	0 270 317	6/88	Europe			
Lg	0 285 357	10/88	Europe		_	1
اما	0 287,210	10/88	Europe		-	
6	0 295 092	12/88	Europe		_	
LA	0 296 740	12/88	Europe		-	1
	0.312.208		Europe (abstract only)			1 - 1 -
50	0 341 745	5/89	Europe	<u> </u>		
40 1	0 244 718	14/87	Europe		-	
4	0 378.852	7/90	Europe		<u> </u>	

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

/		Goodwin, J.S., Prostaglandin E and Cancer Growth: Potential for Immunotherapy	بر
6	•	with Prostaglandin Synthesis Inhibitors, Augmentive Agents in	
	*	Cancer Therapy, Raven Press, New York (1981), pp 393-415	·····
w	ļΓ		
Cp.		Asculai, Dr. S., "Inactivation of Herpes Simplex Viruses by Nonionic	<u> </u>
		Surfactants", Antimicobial Agents and Chemotherapy, 4/78, pp. 686-690	
,	i	Sneader, W.E., Chemical Abstracts, vol. 76, no. 10, "Possible Mechanism for	R
5		Action of DMSO on Percutaeous absorption, J. Pharm. Pharmcol, 1971, 23 (Supp)	

Examiner	۲	rule	Date Considered	6-696

Sheet <u>3</u> of <u>6</u> FORM PTO-1449 U.S. DEPARTMENT OF COMMERCES ATTY DOCKET NO. SERIAL NO. (Rev. 2-32) PATENT AND TRADEMARK OFFICE P-0800(0)-2 08/462,148 Information Disclosure Statement by Applicant Pharmaceutical Corporation (Use several sheets if necessary) ING DATE GROUP 1211 June 5, 1995

U.S. PATENT DOCUMENTS

Exmr Initial	Document Number	Date	Name	Class	Sub Class	Filing Date	٦
	07/338,106	4/89	Falk (application)				۶,
					 		٦,
						†	ヿ
						T	┥.
						<u> </u>	٦.
				· · · · · · · · · · · · · · · · · · ·			ヿ
	:					<u> </u>	7
						 	┪
						İ	┪.
					 	 	7
					 		7

FOREIGN PATENT DOCUMENTS

Exmr	Document Number	Date	Country	Class	Sub Class	Transla YES	uon L NO
10	1,205,031	5/86	Canada	~			
(0)	1,240,929	8/88	Canada				
100	2,031,880	12/90	Canada				
(1)	63/045223	2/88	Japan (w/abstract)	-			
عها	61000017	1/86	Japan (w/abstract)			1.	
- 70	1287041		Japan (abstract only)				
6	62201825	1987	Japan (w/abstract)				
las	62201825	9/87	Japan (translation)	٠		X	
(-	62287041	11/89	Japan (translation)			X	
4	A11678/88	5/88	Japan (laid open) (see 1-287041 above) —	_	X	
ر بر	61-233622	110/86	Japan (w/ abstr)		1	X	i
	57-183707	11/82	Japan (translation) (corrected date)			X	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

,	International Preliminary Examination Report for PCT/CA90/00306 and	\Box
4	attachement substitute claims	
	Alaverdyan et al., "Effect of hyaluronidase, hyaluronic acid, and some	
Gr. 1	other substances on postradiational experimental bacteriemia".	
	Bulletin of Experimental Biology & Medicine 1967: 64(9): 967-969	
w		
	Balazs et al. "The rheological properties and biological funtion of hyaluronic acid".	==
(n)	Chem. and Mol. Biol. of the Intercellular Matrix, Vol. 3, 1970, pp 1241-1253	

Examiner L Pulle Date Considered 66-66			
	Examiner	4 Pelli	Date Considered & GG

Sheet 4 of 6

1211

FORM PTO-1449

(Rev. 2-32)

U.S. DEPARTMENT OF COMMERCE

ATTY DOCKET NO.

SERIAL NO 08/462,148

Information Disclosure Statement by Applicant

FILING DATE
June 5, 1995

GROUP

Pharmaceutical Corporation

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Exmr	Document Number	Date	Name	Class	Sub Class	Filing Date
					<u> </u>	
						<u> </u>
					 	

FOREIGN PATENT DOCUMENTS

Exmt Initial	Document Number	Date	Country	Class	Sub Class	Translat	ion
1	AUB14534/8	8 11/90	Australia (corrected date)			+ 100	110
in	AUB17459/8	8 12/88	Australia			1	
G	B-72117/87	12/87	Australia			1	
in	B-17459/88	12/88	Australia				
4	30806/84	7/84	Australia		‡	+	
60	769,287	3/57	UK		_		
LP	1,283,892	8/72	GB			+	
50	2,099,826-A	12/82	GB			-	
4	2364373	10/75	Germany			\mathbf{x}	
4	WO88/07060	9/88	PCT			+^	-
in	WO89/07932	9/89	PCT		_	+	
	-WO91/04058	4/91	Intrnat'l Search Report (corresponds t	ALL S AT	pl.)		
lr	WO88/07060	9/88	PCT (submitted twice)		<u> </u>	+	
10	WO89/05645	6/89	PCT			+	
					 -		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

_		Balezs E.A. et al. "Hyaluronic acid: Its structure and use", Cosmetics &	
C _r	i	Toiletries, Polymers in Cosmetics 1984; 99: 65-72	
1.		Camber O. et al, "Diffusion of some low molecular weight compounds in sodium	
V	<u> </u>	hyaluronate", Acta Pharmaceutica Suecica 1985; 22(6): 315-320	
,		Camber O. et al. 'Influence of sodium hyaluronate on the meiotic effect of	=
₩.		pilocarpine in rabbits*, Current Eve Research 1987: 6(6): 779-784	
,		Chang S-C, "Prodrug and vehicle approaches to improve the therapeutic index	E
مکر] [of topically applied timolol in the pigmented rabbit", Dissertation	
		Abstracts International 1988; 49(2): 367-B	

Examiner	(Kelle	Date Considered	bber 6

FORM PTO-1449

(Rev. 2-32)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

АТТУ DOCKET NO. 19-90800 (0) -2 Sheet <u>5</u> of <u>6</u>

Information Disclosure Statement by Applicant

REDIG SIT

SERIAL NO. 08/462,148

(Use several sheets if necessary)

Hyal Pharmaceutical Corporation

FILING DATE

GROUP

June 5, 1995

1211

OTHER DOCUMENTS
(Including Author, Title, Date, Pertinent Pages, Etc.)

		2 control of the cont	
	L	Cravioto R O et al, "Effects of Precipitates Formed by Insulin with Hyaluronic	_=
5		Acid and Mucoid from Vitreous Humor in Depressing Blood-Sugar Levels	- '
		Science (1950); Vol. 111: 520-521	_
5		Gieldanowski J et al, "Studies on immunosuppresive and anti-inflammatory	
}	٠ ،	effects of adriamycin", Arch. Immunol. Ther. Exp. (1980); 28(3): 439-446	_
		Hassan, H.G., et al., "Effects of adjuvants to local anaesthetics on	
<i>γ</i> ,	. "	their duration", Acta Anaesthesiol Scand 1985; 29: 384-388	
		Hurd, E.R., "Immunosuppressive and antiinflammatory properties of	
4		cyclophosphamide, azathioprine and methotrexate", Arthritis and	 '
·	Γ	Rheumatism (1973 Jan/Feb); 16(1): 84-88	_
		Idson B, "Polymers in skin cosmetics", Cosmetics & Toiletries 1988; 103: 63-68	_=
4			
		Johansson A. et al, "Effects of adjuvants to local anaesthetics on their	_ _F
y ,	\ \ \ \	duration*, Acta Anaesthesiol Scand 1985; 29: 736-738	<u></u>
		Kalbhen D.A., "The inhibitory effects of steroidal and non-steroidal	
		antirheumatic drugs on articular cartilage in osteoarthrosis and	
\sim		its counteraction by a biological GAG-peptide complex (Rumalon [®])",	_
		Z. Rheumatol (1982): 41: 202-211	_
		Katsu M. et al., "Significance and clinical use of non-steroid anti-inflammatory drugs as	_= +
5	4	substitutes for steroids in steroid dependence", Nippon Rinsho (1986 Jan) 26(1): 89-95	_
		Kreis H et al, "Nonsteroid antiinflammatory agents as a substitute treatment	E
\	*	for steroids in ATGAM-treated cadaver kidney recipients" Transplantation	
r		(1984 Feb); 37(2): 139-145	
		McIlwraith W, "Current concepts in equine degenerative joint disease", Journal of	_ F
·γ _i	``	the Am. Veterinary Medical Assoc. 1982; Feb 1, vol. 180: 239-250	-
		Mizusnima Y., "Possibility of non-steroid anti-inflammatory drugs as a substitute	—.:. .
4		for steroids-analysis of the present situation and demands for the future",	_
- .		Nippon Rinsho (Jan 1986); 26(1): 61-65	_
		Nizolek D.J.H. et al, "Corticosteroid and hyaluronic acid treatments in equine	<u>-</u> _
4	6.	degenerative joint disease: A Review The Cornell Veterinarian 1981: 71(4): 355-375	
-		Pigman W et al. "Acide hyaluronique et facteurs de permeabilite tissulaire"	- F
\	<u> </u>	Bull. Soc. Chim. Biol. 1963; 45(2-3): 185-202	
-1		Pruett RC, et al, "Hyaluronic acid vitreious substitute", In: Vitreous Surgery	
\mathcal{L}_{h}	\ \ \	and Advances in Fundus Diagnosis and Treatment, H. McKenzie Freeman et al	
-	 	Editors, Appleton-Century-Crofts, 1977: Chapter 55, pp. 433-444	_
		Reim M et al. "Surgical procedures in the treatment of most severe eye burns"	
ur	0	Acta Ophthalmologica 1989-Supplementum 192; 67: 47-54	<u> </u>
	<u> </u>	1 Acta Opiniamologica 1707-Supplementum 172, 07. 47-54	_

Examiner (ryh	Date Considered 6.3-96

FORM PTO-1449

(Rev. 2-32)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

Information Disclosure Statement by Applicant

(Use several sheets if necessary)

T NO.

SERIAL NO.

08/462,148

Sheet <u>6</u> of <u>6</u>

+G

imaceutical Corporation

FILING DATE
June 5, 1995

GROUP

1211

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Rydell N et al, "Effect of intra-articular injection of hyaluronic acid on the	-
4	``	clinical symptons of osteoarthritis and on grandulation tissue formation"	
		Clinical Orthopaedics and Related Research 1971: 80 (October): 25-29	
		Saba P et al, "Investigation of antihyperlipemic activity of an association	F
6	-2	of clofibrate and extractive mucopolysaccharide complex", Current	
		Therapeutic Research 1978; 23(4): 455-463	
		Stegmann R et al, "Use of sodium hyaluronate in sever penetrating	
4	•	ocular trauma" Acta Ophthalmol. 1986; 18: 9-13	
Un	-	Trabucchi E et al, "Prevention of wound dehiscense in severely	
		obese patients with jejuno-ileal by-pass: the role of hyaluronic acid"	'-
		Pharmatherapeutica 1988; 5(4): 233-239	
		Sertoli P et al., "L'acido jaluronico, per uso topico, nella cura	F
4		della ulcere trofocircolatorie degli arti inferiori (Comunicazioni)	
	`	Giornale Italiano di Dermatologia 1970; 45(8): 468-471	
		Walther M, "The Prevention of Strine Cutis Distansae During	
Vη		Pregnancy", Minerva Ginecologica (1981) Vo. 33: 497-499	
<u></u>	€.	Weirich E G et al, "Dermatopharmacology of salicyclic acid. III.	
r		Topical contra-inflammatory effects of salicylic acid and other drugs in	
$\mathcal{L}_{\mathfrak{P}}$		animal experiments", Dermatologica (1976); 152(2): 87-99	
		(1)/0), 132(2). 0/-//	
	•		
	<u> </u>		
	1		
]	

Examiner 4	Pey ly	Date Considered 64.6